viewCollagen Solutions PLC

Collagen Sol PLC - Directorate Change

RNS Number : 1694T
Collagen Solutions PLC
13 November 2019

13 November 2019

Collagen Solutions plc

("Collagen Solutions" or the "Company")


Directorate Change


Collagen Solutions Plc (AIM: COS), the developer and manufacturer of biomaterials and regenerative medicines for the enhancement and extension of human life, announces that it has decided to streamline its Board of Directors by limiting the Executive Officers on the Board to only the CEO and CFO, reducing its size from eight members to six.


Lou Ruggiero, Chief Business Officer, and Tom Hyland, Chief Operating Officer, will resign from the Company Board of Directors. Mr. Ruggiero's role with the Company will remain unchanged. Mr. Hyland will transition to a Chief Technical Adviser role in a consulting capacity and the Company does not plan to backfill the Chief Operating Officer position.


Chris Brinsmead, Chairman of Collagen Solutions, commented: "As the Company is preparing for its next stage of growth the time is right to adjust to a slimmer, more efficient executive team and Board. The executive team is highly focused on upgrading our production capabilities, strengthening our technical excellence, and organising the Company around meeting the growing demand for biomaterials product supply, development and contract manufacturing. By streamlining the Board, this enables the executive team to focus on these critical activities, whilst ensuring effective and efficient governance and support of the Board."


Collagen Solutions Plc


Jamal Rushdy, CEO 

Via Walbrook

Hilary Spence, CFO




Cenkos Securities Plc (Nominated Adviser and Broker)


Giles Balleny (Corporate Finance)

Tel: 0207 397 8900

Stephen Keys




Walbrook PR Ltd

Tel: 020 7933 8780 or [email protected] 

Anna Dunphy

Mob: 07876 741 001

About Collagen Solutions:

Collagen Solutions Plc is a global supplier, developer, and manufacturer of medical grade collagen, tissues, and related medical devices and components for use in regenerative medicine, tissue engineering, and research. The Company is also expanding its range of biomaterials-based finished medical devices based on its internal and acquired intellectual property for commercialisation with partners via licensing and distribution arrangements, including ChondroMimetic®. The Company's products are used in a wide variety of applications including orthopaedics, cardiovascular, dental, plastic surgery, wound healing, neurology and urology.

 For more information go to: www.collagensolutions.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

Quick facts: Collagen Solutions PLC

Price: 2.775

Market: LSE
Market Cap: £12.31 m

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...



Morning Report: Vaccines and EU package lift FTSE 100

Headlines from the Proactive UK newsroom. The FTSE 100 was in better heart as yesterday’s vaccine news and €750bn EU bail-out package helped sentiment. The blue-chip index rose 43 points to 6,305. Grocery tills were their busiest ever over the past 12 weeks according to market research...

2 weeks ago